Immune persistence up to one year after a single dose of pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5) administered to children, adolescents and adults (2-29 years of age) in Mali and The Gambia.

A meningococcal ACYWX conjugate vaccine (NmCV-5) has been developed to address epidemic meningitis in Sub-Saharan Africa. During a phase 3 observer-blind clinical trial in 2- to 29-year-olds in Mali and The Gambia, a single dose of either NmCV-5 or a licensed quadrivalent ACYW conjugate vaccine (MenACYW-D) was found to be safe and immunogenic 28 days post-vaccination. Among the original 1800 study participants, a subset of 786 was further evaluated for immune responses by rabbit complement serum bactericidal assay (rSBA) at 6 and 12 months after immunization. At 12 months post-immunization, 100% of NmCV-5 group retained titers ≥128 for serogroups A, Y, and W, 99.8% for X and 90.9% for serogroup C. For the MenACYW-D group, 100% retained titers ≥128 for A, 99.6% for Y, 98.1% for W, 74.8% for serogroup C, and 89.9% for X. The seroresponse rate in the NmCV-5 group was 58% for A, 91.5% for Y, 96.4% for W, 82.6% for X and 89.8% for C. In the MenACYW-D group, the seroresponse rate was 37.6% for A, 86.1% for Y, 92.7% for W, 75.5% for C, and 7.1% for X. Geometric mean titers (GMTs) declined between 28 days and 12 months. At 12 months, in the NmCV-5 group they were at 985 for C and >4096 for all other serogroups. In the MenACYW-D group, GMTs were 269 for C, >2048 for A, W, Y and remained at baseline levels for X. Further investigation is needed at later timepoints to project NmCV-5 duration of protection.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1093/cid/ciag693
Primary Topic
Bacterial Infections and Vaccines
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune persistence up to one year after a single dose of pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5) administered to children, adolescents and adults (2-29 years of age) in Mali and The Gambia.

Jo Anne Welsch, Lionel Martellet, Milagritos Tapia, Ed Clarke et al.
PubMed
Bacterial Infections and Vaccines
article

Immune persistence up to one year after a single dose of pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5) administered to children, adolescents and adults (2-29 years of age) in Mali and The Gambia.

Jo Anne Welsch, Lionel Martellet, Milagritos Tapia, Ed Clarke, Dhananjay Kapse, Mark R. Alderson, Magnus Ochoge, Fatoumata DIALLO, Niranjan Bhat, Yuxiao Tang, Prasad S. Kulkarni, Samba Sow, Fadima Haidara, Ama Umesi, F Marc LaForce, Nancy Hosken
article en

Abstract

A meningococcal ACYWX conjugate vaccine (NmCV-5) has been developed to address epidemic meningitis in Sub-Saharan Africa. During a phase 3 observer-blind clinical trial in 2- to 29-year-olds in Mali and The Gambia, a single dose of either NmCV-5 or a licensed quadrivalent ACYW conjugate vaccine (MenACYW-D) was found to be safe and immunogenic 28 days post-vaccination. Among the original 1800 study participants, a subset of 786 was further evaluated for immune responses by rabbit complement serum bactericidal assay (rSBA) at 6 and 12 months after immunization. At 12 months post-immunization, 100% of NmCV-5 group retained titers ≥128 for serogroups A, Y, and W, 99.8% for X and 90.9% for serogroup C. For the MenACYW-D group, 100% retained titers ≥128 for A, 99.6% for Y, 98.1% for W, 74.8% for serogroup C, and 89.9% for X. The seroresponse rate in the NmCV-5 group was 58% for A, 91.5% for Y, 96.4% for W, 82.6% for X and 89.8% for C. In the MenACYW-D group, the seroresponse rate was 37.6% for A, 86.1% for Y, 92.7% for W, 75.5% for C, and 7.1% for X. Geometric mean titers (GMTs) declined between 28 days and 12 months. At 12 months, in the NmCV-5 group they were at 985 for C and >4096 for all other serogroups. In the MenACYW-D group, GMTs were 269 for C, >2048 for A, W, Y and remained at baseline levels for X. Further investigation is needed at later timepoints to project NmCV-5 duration of protection.

PubMed
University of Maryland, Baltimore (US), Program for Appropriate Technology in Health (US), Serum Institute of India (India) (IN), Centre Pour le Développement des Vaccins-Mali (ML), London School of Hygiene & Tropical Medicine (GB), MRC Unit the Gambia (GM), Medical Research Council (GB)
Bacterial Infections and Vaccines
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon